Impact on efficacy of the dose and schedule of bortezomib in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Melphalan, prednisone and bortezomib (MPV) is a current standard in the treatment of transplant ineligible newly diagnosed multiple myeloma (TI NDMM) and has been used as a control arm in several recent phase 3 clinical trials. Bortezomib related peripheral neuropathy (PN) is a limiting factor to apply the original MPV dose and schedule and reduced intensity schedules have been used both in clinical practice and in clinical trials. However, the feasibility of full-dose MPV and the impact on efficacy of dose intensity in real world have not been described.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Gladys Ibarra, Laura Abril, Marta Pe ña, Albert Oriol Source Type: research
More News: Brain | Clinical Trials | Hematology | Leukemia | Lymphoma | Myeloma | Neurology | Peripheral Neuropathy | Prednisone | Transplants | Velcade